News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Oxford BioMedica PLC License Patents To Emergent BioSolutions In Deal Worth up to $21.4 Million
August 19, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON (Dow Jones)--U.K. biotechnology company Oxford BioMedica PLC (OXB.LN) said Wednesday it licensed rights technology used for the development of vaccines to Emergent Biosolutions Inc. (EBS) for up to $21.4 million.
Twitter
LinkedIn
Facebook
Email
Print
Alliances
Europe
Emergent BioSolutions
MORE ON THIS TOPIC
Deals
Ipsen sends clear Memo to rare diseases with up to $796M buyout
July 1, 2026
·
2 min read
·
Gabrielle Masson
Manufacturing
Eli Lilly and Regeneron among 7 companies picked for FDA PreCheck pilot program
July 1, 2026
·
2 min read
·
Nick Paul Taylor
Podcast
Sentiment at BIO soars as FDA resets, dealmaking evolves; Amgen’s Tavneos in hot water
July 1, 2026
·
2 min read
·
Jef Akst
Insights
Golden Triangle still dominates, but talent and capital gaps slow biotech growth
July 1, 2026
·
3 min read
·
Jennifer C. Smith-Parker
